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Expression of a functional human complement inhibitor in a
transgenic pig as a model for the prevention of xenogeneic
hyperacute organ rejection
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JAMES W. KNIGHT§, WILLIAM VELANDER¶, AND STEPHEN P. SQUINTO*t
*Alexion Pharmaceuticals, Inc., 25 Science Park, New Haven, CT 06511;t Department of Pathology, Yale University School of Medicine, 310 Cedar Street,
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Communicated by George E. Seidel, Jr., June 23, 1994

The serious shortage of human organs availABSTRACT
able for transplantation has engendered a heightened interest
in the use of animal organs (xenografts) for transplantation.
However, the major barrier to successful discordant xenogeneic organ transplantation is the phenomenon of hyperacute
rejection. Hyperacute rejection results from the deposition of
high-titer preformed antibodies that activate serum complement on the luminal surface of the vascular endothelium,
leading to vessel occlusion and graft failure within minutes to
hours. Although endogenous membrane-associated complement inhibitors normally protect endothelial cells from autologous complement, they are species restricted and thus confer
limited resistance to activated xenogeneic complement. To
address the pathogenesis of hyperacute rejection in xenotransplantation, transgenic mice and a transgenic pig were engineered to express the human terminal complement inhibitor
hCD59. High-level cell surface expression of hCD59 was
achieved in a variety of murine and porcine cell types, most
importantly on both large vessel and capillary endothelium.
hCD59-expressing porcine cells were signicantly resistant to
challenge with high-titer anti-porcine antibody and human
complement. These experiments demonstrate a strategy for
developing a pig-to-primate xenogeneic transplantation model
to test whether the expression of a human complement inhibitor
in transgenic pigs could render xenogeneic organs resistant to
hyperacute rejection.

complement regulatory proteins normally protect endothelial
cells from autologous complement. However, the activity of
these complement inhibitors is species restricted. This property makes them relatively ineffective at inhibiting xenogeneic serum complement (9, 10). The demonstration that a
human complement inhibitor could protect a xenogeneic cell
from human complement-mediated lysis showed that it was
possible to inhibit human anti-porcine hyperacute rejection in
in vitro models (11).
The strategy used to address the pathogenesis of hyperacute rejection in the porcine-to-primate xenotransplantation
model was to produce transgenic swine expressing high levels
of the human terminal complement inhibitor hCD59. hCD59
is an 18- to 20-kDa glycosyl-phosphatidylinositol-anchored
cell surface glycoprotein that is expressed in a variety of
tissues of both hematopoietic and nonhematopoietic lineage
and functions to inhibit formation of the membrane attack
complex by binding to membrane C5b-8 and C5b-9 (9, 10).
Stable expression of hCD59 on xenogeneic cells in vitro
protected the cells from human complement-mediated cell
lysis (12-14) and the level of protection was directly proportional to the number of molecules of hCD59 expressed on the
surface of the xenogeneic cell (14). Importantly, hCD59expressing porcine aortic endothelial cells were resistant not
only to cell lysis but also to complement-mediated formation
of a procoagulant surface when challenged with either human
or baboon serum (15). Taken together, these results indicated
that high-level expression of hCD59 could provide porcine
tissue with significant protection from human serum complement in a xenotransplantation setting. Therefore, hCD59
was chosen as a candidate molecule for production of transgenic swine resistant to human complement. In this report,
we demonstrate the successful production of a transgenic pig
expressing high levels of hCD59 that protect the pig cells from
human complement-mediated cell lysis.

The lack of effective therapies aimed at eliminating antibodyand complement-mediated hyperacute rejection presents a
major barrier to the successful transplantation of discordant
animal organs into human recipients (1-6) and has precluded
the development of animal models aimed at evaluating the in
vivo cellular immune response to discordant xenografts. Old
World primates, including humans, have high levels of preexisting circulating natural antibodies that predominantly
recognize carbohydrate determinants expressed on the surface of xenogeneic cells from discordant species (2-6). Recent evidence indicates that most of these antibodies react
with the carbohydrate epitope, Gal(al-3)Gal (7), an epitope
absent from Old World primates because of a lack of the
functional a-1,3-galactosyltransferase enzyme (8). Therefore, after transplantation of a vascularized xenogeneic donor
organ into a primate recipient, the massive inflammatory
response that ensues from natural antibody activation of the
classical complement cascade leads to activation and destruction of the vascular endothelial cells and ultimately of
the donor organ within minutes to hours after revascularization (2-6). Endogenously expressed membrane-associated

MATERIALS AND METHODS
H2Kb-hCD59 DNA Construct, Purification, and Microinjection. A hCD59 cDNA was directionally cloned into exon
1 of the murine H2Kb-gene 12 nucleotides downstream of the
transcriptional start site. Briefly, the hCD59 cDNA fragment
was excised from a hCD59-pcDNAI-Amp (pcDNAI-Amp;
Invitrogen) expression plasmid by digestion with Hindll,
followed by enzymatically filling in the 5' 4-nucleotide overhang with T4 DNA polymerase and dNTPs. Subsequently,
Abbreviations: MHC, major histocompatibility complex; PBMCs,
peripheral blood mononuclear cells; mAb, monoclonal antibody;
PHA, phytohemagglutinin; FITC, fluorescein isothiocyanate;
hrTNF-a, human recombinant tumor necrosis factor a; IFN, interferon.
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the DNA was digested with Not I at the 3' end of the multiple
cloning site of the vector to yield a 452-bp cDNA fragment.
The 9.0-kbp EcoRI H2Kb genomic restriction fragment (16)
cloned into pGEM7Z (Promega) was digested with Nru I and
Not I, resulting in the removal of 51 nucleotides from the
H2Kb gene including the ATG start codon. The hCD59 cDNA
was then directionally ligated into the H2Kb gene in the
pGEM7Z vector.
Purification of the H2Kb-hCD59 DNA for embryo injection was accomplished by digesting the plasmid with Xho I to
remove the vector sequences followed by agarose gel electrophoresis, electroelution, and Elutip purification (Schleicher & Schull). Transgenic mice were produced by pronuclear microinjection of murine ova as described (17). Ten of
60 offspring were identified as transgenic founder animals by
DNA slot blot hybridization (18) (data not shown). Transgenic swine were generated by porcine embryo injection (19).
A total of 18 piglets were analyzed by DNA slot blot analysis
of genomic DNA (18). One founder animal, H2Kb-hCD59
153-2, contained 10-20 copies of the H2Kb-hCD59 DNA.
Two additional founder animals, H2Kb-hCD59 152-1 and
H2Kb-hCD59 152-2, contained =1 copy of the H2Kb-hCD59
DNA and exhibited no expression or very low and inconsistent levels of expression in peripheral blood mononuclear
cells (PBMCs) (data not shown). These animals were not
analyzed further.
Cell Culture, Immunofluorescence, and Immunohistochembtry. PBMCs from transgenic and negative littermate control
pigs were purified from whole blood by Ficoll gradient
centrifugation (ref. 20, pp. 7.1.1-7.1.2). Adherent monocytic
mononuclear cells were cultured in Dulbecco's modified
Eagle's medium/15% fetal bovine serum. PBMCs from transgenic mice and negative littermate control animals were
purified from whole blood by ACK lysis (Biofluids, Rockville, MD). Indirect immunofluorescence of porcine PBMCs
was performed with the anti-hCD59 mouse monoclonal antibody (mAb) MEM-43 (Biodesign International, Kennebunkport, ME) and with the anti-swine leukocyte antigen
(SLA) class I mAb PT85A (VMRD, Pullman, WA). Indirect
immunofluorescence of murine PBMCs was performed with
polyclonal antisera specific for hCD59 (P. Sims, Blood Research Institute, Milwaukee). Goat anti-rabbit IgG (polyclonal sera; Zymed) or goat anti-mouse IgG (monoclonal sera;
Zymed) fluorescein isothiocyanate (FITC)-conjugated antisera were used to detect specific antibody binding to the cell
surface. Cell surface expression was then measured by flow
cytometry on a Becton Dickinson FACSort.
The cytokine inducibility of H2Kb-hCD59 and the endogenous porcine SLA class I molecule was tested on adherent
peripheral blood monocytes. Briefly, porcine cytokineconditioned medium supernatants were produced from control pig PBMCs. PBMCs harvested from a control pig were
stimulated with phytohemagglutinin (PHA; 5 pg/ml) for 48 h.
PHA-conditioned media were collected and treated with 10
mM methyl a-mannoside and filter sterilized. Human recombinant tumor necrosis factor a (hrTNF-a; Collaborative
Biomedical Products, Bedford, MA) was used at 500 units/
ml. Adherent peripheral blood monocytes were then treated
with medium alone, 50% PHA-conditioned medium (diluted
1:1 with complete medium), 50% PHA-conditioned medium/
hrTNF-a, or hrTNF-a for 24 h. Cytokine-induced expression
of hCD59 and SLA class I was detected by immunofluorescence and fluorescence-activated cell sorter analysis as described above.
Immunohistochemistry was performed on fresh frozen
sections embedded in Tissue-Tek OCT compound (Miles).
Tissue sections (5-10 ,um) were processed as described (ref.
20, pp. 5.8.1-5.8.2). Sections that were double stained were
processed simultaneously with the mouse anti-hCD59 mAb,
MEM-43 (20 ,ug/ml), and the anti-type IV collagen rabbit
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polyclonal antiserum (21) (1:50 dilution). Fluorochromeconjugated goat anti-mouse IgG and goat anti-rabbit IgG
antisera were used to detect specific antibody interactions
with the hCD59 antigen (goat anti-mouse rhodamine; AMAC,
Westbrook, ME) and type IV collagen antigen (goat antirabbit FITC; Zymed).
Complement-Mediated Dye Release Assays. PBMCs or peripheral blood adherent cells were labeled with the intracellular dye Calcein AM (Molecular Probes). The cells were
subsequently incubated with anti-porcine blood cell IgG (2
mg/ml) (Intercell Technologies, Hopewell, NJ) followed by
incubation in increasing concentrations of human whole
serum (Sigma) at 37TC for 30 min. Dye released from the cells
was determined by flow cytometry on a Becton Dickinson
FACSort. The C5b-9-specific dye release was calculated as
percentage of total, correcting for nonspecific dye release and
background fluorescence measured on identically matched
controls without the addition of serum. Antibody blocking
experiments were performed by the complement-mediated
dye release assay as described above with the following
exceptions. The cells were incubated in 20% C8-deficient
serum (C8d; Quidel, San Diego) at 37TC for 30 min after
anti-porcine blood cell antibody activation. The cells were
then incubated with hCD59 polyclonal antiserum (100 pg/ml)
or anti-SLA class I antiserum PT85A (100 pg/ml). Purified
human C8 (Quidel) and C9 (Quidel) complement components
were then added in increasing concentrations and incubated
at 37TC for 30 min. Dye released from the cells was detected
by flow cytometry on a Becton Dickinson FACSort as
described above.
RESULTS
Transgenic Expression. To achieve expression of the transgene-encoded hCD59 we engineered a murine major histocompatibility complex (MHC) class I gene, H2Kb (16), to
control the expression of a hCD59 cDNA, H2Kb-hCD59
(Fig. 1). The MHC class I gene is ubiquitously expressed on
most somatic cells and, most importantly, is a predominant
endothelial cell surface antigen (22, 24). In addition, the MHC
class I promoter contains cis-acting regulatory elements that
bind cytokine-inducible trans-acting factors, resulting in upregulation of the class I gene upon stimulation with interferon
(IFN)-a/13, IFN-y, and TNF-a (22-25). A hCD59 cDNA was
cloned into exon I of H2Kb and results in a transcript that
initiates at the H2Kb transcriptional start site and proceeds
through both the cDNA insert and the entire transcriptional
unit of the H2Kb gene. Translation initiates at the ATG codon
of the inserted cDNA and terminates at the cDNA stop
codon. The rest of the H2Kb gene remains untranslated and
functions only in RNA processing, providing the cDNA with
a genomic structure that contains all the regulatory elements
required for H2Kb expression (22-25).
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FIG. 1. H2Kb genomic cassette. A linear representation of the
hybrid gene construct detailing the exon-intron structure of H2Kb
and the insertion of the hCD59 cDNA into exon 1.
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The efficacy of the H2Kb-hCD59 genomic expression
construct in directing cell surface expression of hCD59 in
various tissues was tested in transgenic mice and pigs. Initial
analysis demonstrated that the H2Kb-hCD59 genomic construct directed the expression of hCD59 on the surface of
PBMCs in several founder transgenic mice and transgenic pig
153-2 (Fig. 2 A and B, respectively). Importantly, expression
of hCD59 on the surface of the porcine mononuclear cells
paralleled that of SLA class I (Fig. 2B). The comparable
expression of hCD59 to SLA class I indicated that the murine
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H2Kb-hCD59 chimeric gene was constitutively regulated,
similar to the endogenous porcine SLA class I molecules. To
establish whether the H2Kb-hCD59 chimeric gene exhibited
cytokine inducibility comparable to the endogenous SLA
class I gene, we cultured adherent monocytic PBMCs. Interestingly, after prolonged culture, these monocytes had
downregulated cell surface expression of both SLA class I as
well as the hCD59 transgene-encoded protein (compare Fig.
2B, curve b, to Fig. 2D, curve b for class I and Fig. 2B, curve
a, to Fig. 2C, curve b, for hCD59). Treatment of the transgenic porcine cells with PHA-induced cytokine-conditioned
medium, with hrTNF-a, or with a combination of the treatments resulted in an increase in hCD59 expression (Fig. 2C)
as well as an increase in SLA class I expression (Fig. 2D).
We next examined hCD59 expression on the endothelium
of vascularized organs. Immunohistochemical analyses were
performed on fresh-frozen tissue sections derived from
hCD59 transgenic mice and pigs as well as from nontransgenic littermates. Phase-contrast micrographs illustrating the
structure of mouse myocardium are shown in Fig. 3 A and D.
Tissue sections from three founder mice were analyzed for
hCD59 expression. Mouse hearts were incubated with anticollagen type IV polyclonal antisera to detect basement
membrane structures underlying the endocardium as well as
intramyocardial capillary endothelia (21). Fig. 3 B and E,
respectively, confirmed equivalent collagen staining in the
negative littermate control and a representative hCD59 transgenic mouse, H2Kb-hCD59-8. In contrast, staining with a
mAb specific for hCD59 revealed intense cell surface expression on endothelial cells in the heart of transgenic mouse
H2Kb-hCD59-8 (Fig. 3F) and an absence of hCD59 expression in the negative littermate control (Fig. 3C). Fig. 3F
dramatically highlights the expression of hCD59 on vascular
structures and clearly shows high-level expression of hCD59
on the endocardium in the ventricular chamber. Abundant
hCD59 was also detected on capillary vessels within the
myocardium (Fig. 3F). All three founder transgenic mice
analyzed revealed hCD59 staining on the endocardium and
capillary endothelium. To evaluate vascularized structures in
the transgenic pig without having to sacrifice the founder
animal, tail sections were prepared and analyzed by immunohistochemistry as described for the mice. Phase-contrast
micrographs illustrate the morphological structure of a tail
artery from a negative control pig (Fig. 4A) and a tail artery

U_
Log fluorescence intensity
FIG. 2. Cell surface expression of hCD59 in transgemc mice and
a transgenic pig. (A) Expression of hCD59 on murine PBMCs
detected in transgenic mice H2Kb-CD59-11 (curve a), H2KbCD59-23 (curve b), H2Kb-CD59-21 (curve c), and a negative littermate control (curve d). (B) Cell surface expression of hCD59 and
SLA class I detected on porcine PBMCs. Curve a, hCD59 expression
in transgenic pig H2Kb-hCD59 153-2; curve b, SLA class I expression in transgenic pig H2Kb-hCD59 153-2; curve c, negative littermate control PBMCs incubated with the hCD59 mAb. (C) Cytokineinduced cell surface expression of hCD59 on cultured adherant
PMBCs from pig H2Kb-hCD59 153-2; goat-anti-mouse FITC control
antisera (curve a); hCD59 expression on uninduced cells (curve b);
hrTNF-a (curve c); PHA conditioned medium (curve d); PHA
conditioned medium + hrTNF-a (curve e). (D) Cytokine-induced cell
surface expression of SLA class I on cultured adherent PBMCs from
pig H2Kb-hCD59 153-2; goat-anti-mouse FITC control antiserum
(curve a); uninduced cells (curve b); hrTNF-a (curve c); PHA
conditioned medium (curve d); PHA conditioned medium +
hrTNF-a (curve e).
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FIG. 3. Double-label immunofluorescence microscopy of hCD59
and type IV collagen on murine heart tissue from a H2Kb-hCD59
transgenic mouse and a negative littermate control. Phase-contrast
micrographs of murine ventricular myocardium (A and D). L, lumen
of the left ventricle lined by endothelial cells. (B and E) Immunofluorescence micrographs detecting type IV collagen (fluorescein) of
the same myocardial sections illustrating basement membrane structures underlying the endocardium. Immunofluorescence micrographs (rhodamine) of the same myocardial sections detecting hCD59
in a negative littermate control (C) and H2Kb-hCD59-8 (F). (x400.)
(Bar = 25 gm.)
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FIG. 4. Immunofluorescence microscopy of hCD59 on swine tail
sections from pig H2Kb-hCD59 153-2 and a negative littermate
control. (A) Phase-contrast micrograph of a dermal artery from the
negative littermate illustrating the lumen (L), the endothelial cell layer
(arrow), and the tunica media (m). (B) Immunofluorescence micrograph (rhodamine) of the same section pictured in A, illustrating the
lumen, the endothelial cell layer, and the tunica media. (C) Phasecontrast micrograph of a dermal artery from pig H2Kb-hCD59 153-2,
illustrating the lumen, the endothelial cell layer, and the tunica media.
(D) Immunofluorescence micrograph (rhodamine) ofthe same section
pictured in C, illustrating the lumen, the endothelial cell layer, and the
medial smooth muscle cells (m). (E) Phase-contrast micrograph of a
dermal microvessel from pig H2Kb-hCD59 153-2, illustrating the
lumen and the vessel wall. (F) Immunofluorescence micrograph
(rhodamine) of the same section pictured in E, illustrating the lumen,
and an abundance of hCD59 expression. (x400.) (Bar = 25 um.)

and small vessel from the transgenic founder pig 153-2 (Fig.
4 C and E, respectively). High-level hCD59 expression was
observed on a variety of tissue and cell types, including
fibroblasts, epithelial cells, vascular endothelial cells, and
smooth muscle cells within the tail section of the transgenic
pig (Fig. 4 D and F) but not in the negative littermate (Fig.
4B). Not all tissue in the transgenic pig tail section revealed
hCD59 staining; however, tissues such as striated muscle are
known to express very low levels of the class I antigen and
therefore would not be expected to express the class I-regulated hCD59 transgene (24). These analyses confirmed that
the H2Kb-hCD59 genomic construct directed expression of
hCD59 to a variety of cells and tissues in transgenic pig 153-2
and, most importantly, to the surface of vascular endothelial
cells.
Complement Resistance. To determine whether the high
levels of transgene expression observed on the transgenic pig
cells conferred significant protection from human complement-mediated attack, functional analyses were performed
on hCD59-expressing porcine PBMCs collected from transgenic pig 153-2 and a nontransgenic littermate control. The
data clearly demonstrated that hCD59-expressing porcine
cells, but not cells from a nontransgenic littermate, significantly resisted human complement-mediated lysis (Fig. SA).
The percentage dye released from hCD59 protected cell was
-5-fold less when compared with the amount of dye released
from negative littermate control cells. To confirm that the
protection observed in PBMCs was due specifically to hCD59
expression, antibody blocking experiments were performed.
As shown in Fig. SB, the anti-hCD59 polyclonal antisera
blocked the hCD59-mediated protection, resulting in an increased susceptibility of the porcine cells to human complement-mediated cell lysis. In contrast, the control antibody
had no effect.
To evaluate whether the degree of protection of porcine
cells from human complement attack was a function of the
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FIG. 5. Complement-mediated dye release assays on porcine
PBMCs and cultured peripheral blood adherent cells. (A) Dye release
assay performed on porcine PBMCs (*), transgenic pig H2KbhCD59 153-2; (A), negative littermate control. (B) Dye release assay
performed on PBMCs from transgenic pig H2Kb-hCD59 153-2
incubated in the presence of anti-hCD59 polyclonal antiserum (*);
control class I antibody PT85A (e); negative littermate control
PBMCs incubated in the presence of anti-hCD59 polyclonal antiserum (A); control class I antibody PT8SA (o). (C) Complementmediated dye release assays on porcine peripheral blood adherent
cells from pig H2Kb-hCD59 153-2; uninduced cells (A), PHA supernatants (n), PHA supernatants + hrTNF-a (A), hrTNF-a (e), and
control negative littermate cultured peripheral blood adherent cells
(0).

level of hCDS9 expressed on the cell surface, experiments
cultured monocyte lines derived from
the H2Kb-hCDS9 153-2 transgenic pig, which showed increased cell surface expression in response to cytokine
treatments (see Fig. 2). Significantly, these monocytes demonstrated increased susceptibility to human complementmediated lysis, consistent with the loss of hCDS9 expression
(Fig. 5C). As previously shown, culture of these cells in the
presence of cytokines known to induce the MHC class I
promoter-i.e., IFN-'y and TNF-a.--upregulated hCDS9 expression (Fig. 2C). Importantly, upregulating hCDS9 expression restored their complement-resistant phenotype (Fig.
SC). These results confirm that the level of transgene expression correlates with cellular protection and also highlight
the potential utility of the inducible H2Kb promoter in the
setting of a cytokine-mediated inflammatory response.

were performed on the
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DISCUSSION
Expression of human complement inhibitor hCD59 was established in transgenic mice and in a transgenic pig utilizing
the murine MHC class I gene as a genomic expression
cassette. The proteins encoded by the MHC class I genes
from human (HLA), mouse (MHC), and swine (SLA) are
expressed in most somatic cell types including the vascular
endothelium (22, 24, 26). Therefore, a MHC class I promoter
should direct high-level transgene expression in the endothelial cells of vascularized organs. The additional advantage to
this genomic expression strategy is that the class I promoter
has the capacity to upregulate hCD59 expression in response
to the inflammatory cytokines IFN- y and TNF-a (22, 24, 25).
We have approached the problem of complement-mediated
hyperacute rejection during pig-to-primate xenotransplantation by engineering the xenogeneic donor tissue with human
complement inhibitor hCD59. The analyses of hCD59 in
H2Kb-hCD59 transgenic mice and transgenic pig 153-2 demonstrated that the H2Kb-hCD59 genomic construct regulated
the expression of hCD59 in the context of a transgenic
genome. Cell surface expression of hCD59 was detected in a
variety of cells and tissues, including the vascular endothelium. The assays used to determine the protective effects of
hCD59 expressed on the transgenic cells were performed
with human whole serum, which contains serum complement
components, as well as high-titer natural antibodies (W.L.F.
and S.A.R., unpublished data). In addition, anti-porcine
lymphocyte antiserum was used to enhance the activation of
the classical complement pathway on the surface ofthe target
cell. Our data demonstrated that the level of hCD59 expressed on the cell surface protected the xenogeneic cell even
in the presence of additional complement-activating antibodies.

The utility of blocking complement as a method to prevent
hyperacute rejection in pig-to-primate xenotransplantation
was demonstrated by using cobra venom factor (CVF) and
recombinant soluble complement receptor type 1 (sCR1)
(refs. 27 and 28, respectively). A significant delay of complement-mediated hyperacute rejection in pig-to-primate heterotopic cardiac xenotransplantation was observed with the
administration of CVF for two consecutive days before
transplantation (27) or with a single intravenous bolus of
sCRi before xenograft reperfusion (28). The advantage of
developing a transgenic donor animal expressing a human
complement inhibitor is to provide the donor tissue with an
endogenously expressed membrane-bound inhibitor and
therefore does not rely on repeated administration of pharmacological agents.
The successful engineering of transgenic swine expressing
a human complement inhibitor, and the demonstration that
cells from these animals were significantly protected from
human complement attack, suggests that this strategy may
represent a useful component of an overall approach to
discordant xenotransplantation. This transgenic approach
will hopefully make porcine-to-primate transplantation models feasible that will allow the cellular aspects of discordant
xenograft rejection to be evaluated. In addition, the production of porcine organs resistant to hyperacute rejection may
open therapeutic windows for organ transplantation into
humans, particularly when this technology is coupled with
advances in cellular immunosuppressive regimens.
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